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S100A15, an Antimicrobial Protein of the Skin:
Regulation by E. coli through Toll-Like Receptor 4
Amanda S. Bu¨chau1,2, Mohamed Hassan1, Gabriela Kukova1, Virginia Lewerenz1, Sabine Kellermann1,
Jens U. Wu¨rthner3,6, Ronald Wolf4, Markus Walz1, Richard L. Gallo2 and Thomas Ruzicka5
E. coli is a Gram-negative bacterium rarely found on human skin. We investigated whether direct interaction of
E. coli with keratinocytes might induce an innate immune response through recognition by pattern recognition
receptors. The capacity of E. coli to activate innate immune responses and IL-8 induction was investigated. We
found that E. coli significantly induced human S100A7 and S100A15 transcript abundance and IL-8 release in
cultured primary human keratinocytes. S100A15 is a member of the S100 protein family with previously
unknown function. E. coli induced effects could be inhibited by neutralizing Toll-like receptor 4 (TLR4)
antibodies, suggesting that E. coli-induced IL-8 and S100A15 expression in human keratinocytes are TLR4
dependent. TLR4/ mice lacked elevated mS100A15 expression after infection with E. coli in contrast to wild-
type mice. In vitro, human S100A15 displayed antimicrobial activity against E. coli. Our findings suggest that
E. coli modulates S100A15 and IL-8 expression of keratinocytes by recognition through TLR4.
Journal of Investigative Dermatology (2007) 127, 2596–2604; doi:10.1038/sj.jid.5700946; published online 12 July 2007
INTRODUCTION
S100 proteins comprise a family of small cationic proteins
and are characterized by two calcium-binding EF-hand motifs
with specific calcium-dependent and calcium-independent
interactions (for review see Donato, 2001; Santamaria-Kisiel
et al., 2006). Today, 21 proteins of the S100 family are
known, of which eleven (S100A2, S100A3, S100A4, S100A6,
S100A7 (psoriasin), S100A8, S100A9, S100A10, S100A11,
S100A12, and S100A15) are expressed within the human
epidermis or in normal human epidermal keratinocytes
(NHEKs) (Wolf et al., 2003; Eckert et al., 2004). These
proteins play a role in the pathogenesis of many epidermal
diseases (Donato, 2001; Eckert et al., 2004; Foell and Roth,
2004) and antimicrobial properties were found for several
members of the S100 family, including S100A7, S100A8,
S100A9, and S100A12 (Gottsch et al., 1999; Cole et al.,
2001; Gla¨ser et al., 2005). The recently identified human
S100A15 protein is highly homologous to S100A7 (93%
identity), followed by S100A11 (34%) and S100A8 (29%)
(Wolf et al., 2003). Genomic analysis of S100A7 and
S100A15 encoding chromosomal regions furthermore reveals
that both genes must have evolved by gene duplication
during primate evolution, forming an innate subfamily in man
(Kulski et al., 2003). Human S100A15 is mapped to the S100
gene cluster within the epidermal differentiation complex on
chromosome 1q21 and has two alternatively spliced mRNA-
isoforms, a short (0.5 kb), S100A15S, and a long (4.4 kb),
S100A15L, isoform resulting from different non-coding
regions (Wolf et al., 2003), both coding for the S100A15
protein. The functional relevance of these splice variants is
not known yet. Alternative splicing has been reported only for
human S100A4 from the S100 family so far (Ambartsumian
et al., 1995).
Recently, the murine S100A15 (mS100A15) has been
identified and found to parallel genomic organization,
structure, gene expression, and protein-processing pattern
of the human S100A7/A15 subfamily (Wolf et al., 2006). The
murine S100A15 was mapped to a single genomic region on
chromosome 3qF1, which is the murine equivalent of the
human epidermal differentiation complex. Splice variants as
described for human S100A15 have not been identified for
the murine mRNA of S100A15.
Little is known about the regulation and function of
S100A15. We previously showed that S100A15 is expressed
in healthy skin and is highly upregulated in psoriatic lesional
and non-lesional skin (Wolf et al., 2003, 2006), suggesting a
distinct role in epidermal maturation. Many antimicrobial
peptides (AMPs) and proteins, including members of the S100
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family (S100A7, S100A8, S100A9), b-defensins, and cathe-
licidin are overexpressed in psoriasis but most AMPs and
proteins are also constitutively expressed in healthy skin
(Frohm et al., 1997; Mirmohammadsadegh et al., 2000; Wolf
et al., 2003; de Jongh, 2005; Harder and Schro¨der, 2005),
where they exert a broad spectrum of protective activity.
However, although still many different bacterial strains
survive on the skin, E. coli is rapidly killed (Bevins, 2005;
Gla¨ser et al., 2005). In vitro and in vivo E. coli killing activity
has been demonstrated for S100A7 and other AMPs (Lehrer
et al., 1989; Gla¨ser et al., 2005; Dorschner et al., 2006).
Based on these observations, we hypothesized that S100A15
may be involved in cutaneous innate immune function and
might have antimicrobial function against E. coli. In this
study, we find that E. coli stimulation strongly induced
expression of S100A15 in vitro and in vivo and this was
mediated by Toll-like receptor 4 (TLR4). In addition, we
demonstrate that S100A15 is antimicrobial against E. coli.
RESULTS
Various bacterial species differentially induce S100A15S,
S100A15L, and S100A7 gene expression in human epidermal
keratinocytes
S100A15 expression has been detected in low levels in
healthy skin and at increased levels in psoriasis (Wolf et al.,
2003). Furthermore, S100A15 is constitutively expressed in
cultured human epidermal keratinocytes and is inducible by
proinflammatory cytokines and interleukin 1b (unpublished
data). We therefore investigated if other inflammatory stimuli
such as bacterial compounds affect expression of S100A15
splice variants. To analyze the effect of various bacteria on
S100A15S, S100A15L, and S100A7 mRNA levels, cultured
human keratinocytes were treated for 24 hours with or
without E. coli, Pseudomonas aeruginosa, or Staphylococcus
aureus and their supernatants (Table 1). To confirm that heat-
killed bacteria were biologically active, we examined E. coli-
induced NF-kB and activator protein-1 (AP-1) activation in
NHEK by electromobility shift assay (EMSA) and supershift
assay (Figure 1). Here, we found that unstimulated keratino-
cytes contained a low but detectable, basal level of AP-1 and
NF-kB binding activity, which is consistent with data of other
authors (Qin et al., 1999; Komine et al., 2000). Exposure of
keratinocytes to heat-killed E. coli and its supernatant led to
an induction of a strong AP-1 and NF-kB binding activity
within 3 and 24 hours (Figure 1a). Furthermore, examining
the effect of E. coli and its supernatant, a more pronounced
effect of E. coli-stimulated NHEK, was observed (Figure 1a).
In addition, we ascertained the specificity of both, AP-1 and
NF-kB binding, following the incubation of the nuclear
extracts obtained from human keratinocytes treated with E.
coli, with antibodies directed to c-jun in the case of AP-1
complex or to p50 and p65 subunits in the case of NF-kB
complex by EMSA. The binding of the antibodies to their
specific proteins c-jun or p50 or p65 shifted the specific
bands of AP-1 or NF-kB to higher molecular weight (Figure 1b),
Table 1. Regulation of human S100A15S, S100A15L, and S100A7 mRNA in NHEK upon stimulation with E. coli,
Pseudomonas aeruginosa, and Staphylococcus aureus
Gene bacteria E. coli E. coli supern. P. aeruginosa P. aeruginosa supern. S. aureus S. aureus supern.
S100A15S 2.9770.45* 0.9970.38 1.1470.48 2.8970.71* 1.6770.43 1.9471.03
S100A15L 10.5471.78*** 6.1670.74** 7.3572.34*** 6.9571.89*** 3.8670.96* 3.7471.08*
S100A7 7.6271.93*** 3.2271. 74 5.6772.03** 2.3470.56 1.5470.84 1.2470.63
NHEK, normal human epidermal keratinocyte; P. aeruginosa, Pseudomonas aeruginosa; RT, reverse transcription; S. aureus, Staphylococcus aureus; supern.,
supernatant.
Heat-killed bacteria and bacteria-derived supernatants were used to stimulate NHEK for 24 hours. Semiquantitative RT-PCR was performed. Table 1
indicates the fold increase of relative gene expression (densitometric quantification of S100A15S, S100A15L, and S100A7 mRNA each over the b-actin
mRNA transcript) over constitutive expression. Each number represents the mean7SD of three independent experiments each performed in duplicates.
*Po0.05, **Po0.01, ***Po0.001.
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Figure 1. Induction of AP-1 and NF-jB DNA-binding activities by E. coli in
NHEK. NHEKs were stimulated with heat-killed E. coli or its supernatant for 3
and 24 hours. Nuclear extracts were prepared and equal amounts of nuclear
proteins (B4 mg) were analyzed for the activation of either AP-1 or NF-kB.
The specificity of the DNA-binding activity was analyzed by competition with
unlabeled oligonucleotides. Vehicle-treated keratinocytes contained a low
but detectable basal level of AP-1 and NF-kB binding activity. (a) Exposure of
NHEK to heat-killed E. coli and its supernatant led to an induction of AP-1 and
NF-kB binding activity within 3 hours. (b) Supershift analysis and specificity of
AP-1- and NF-kB-induced activities by E. coli in human keratinocytes.
Nuclear extracts from human keratinocytes stimulated with bacterial
components were incubated with antibodies to c-jun or to p50 and/or to p65.
The data shown are representative of two independent experiments. (a) Lane
1: nuclear extracts obtained from NHEK incubated with unlabeled
oligonucleotide, lanes 2 and 5: vehicle-treated NHEK, lanes 3 and 6: E. coli
supernatant-treated NHEK, lanes 4 and 7: E. coli-treated NHEK; (b) lane 1:
with anti-c-jun antibody, lane 2: without anti-c-jun antibody, lane 3: nuclear
extracts obtained from NHEK incubated with unlabeled oligonucleotide, lane
4: without anti-p50 and anti-p65 antibodies, lane 5: with anti-p50 antibody,
lane 6: with anti-p50 and anti-p65 antibody.
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demonstrating the specificity of AP-1- and NF-kB-induced
activities. The levels of S100A15S, S100A15L, and S100A7
transcript abundance were analyzed by semiquantitative
reverse transcription (RT)-PCR using specific primers (Ta-
ble 1). Here, we found that E. coli and its supernatant
differentially upregulated expression of S100A15S,
S100A15L, and S100A7 mRNA in NHEK after 24 hours of
stimulation (Table 1). P. aeruginosa and its supernatant
induced increased mRNA levels of both isoforms of S100A15
and S100A7 (Table 1). Stimulation with S. aureus and its
supernatant resulted in an increase in S100A15S and
S100A15L mRNA, the expression of S100A7 mRNA was
not significantly affected by stimulation with either S. aureus
or its supernatant (Table 1). From all bacteria tested, E. coli
showed the strongest induction of S100A15. In order to
further evaluate E. coli-induced S100A15 and S100A7 gene
expression, time course experiments were performed. NHEKs
were stimulated with E. coli for 3, 24, or 96 hours (Figure 2).
Here, S100A15S, S100A15L, and S100A7 were significantly
upregulated after 24 hours (Figure 2a–c) and S100A15L and
S100A7 were further increased after 96 hours of stimulation
with E. coli (Figure 2b and c). E. coli is a Gram-negative
ubiquitous bacterium that contains lipopolysaccharide (LPS)
in its cell wall. To evaluate if E. coli-derived LPS alone is
effective to regulate S100A15 and S100A7 gene expression,
NHEKs were co-incubated with E. coli-derived LPS for
24 hours. Consistent with our data derived from heat-killed
E. coli, also E. coli-derived LPS upregulated S100A15L and
S100A7 gene expression, whereas lower S100A15S expres-
sion was observed (Figure 2d).
A neutralizing TLR4 antibody suppresses E. coli-induced
expression of S100A15L and IL-8 release in NHEK
In vitro and in vivo studies indicate that the pattern
recognition receptor TLR4 primarily mediates cellular signal-
ing induced by Gram-negative bacteria (Poltorak et al., 1998;
Takeuchi et al., 1999). E. coli is therefore a predicted
activator of TLR4 (Beutler, 2002; Takeda et al., 2003). TLR4 is
a member of 11 TLRs identified in man and is constitutively
expressed on NHEK (Song et al., 2002; Pivarcsi et al., 2003;
Lebre et al., 2007). TLR activation initiates a signaling
cascade including nuclear translocation of NFkB and
proinflammatory cytokine release (Takeda et al., 2003).
To investigate whether E. coli-mediated effects on the
expression of S100A15 are mediated through TLR4, before
stimulation with E. coli, NHEKs were treated with a TLR4
neutralizing antibody (anti-TLR4) or an isotype IgG control
antibody for 30 minutes and expression of S100A15L and
S100A15S and the release of IL-8 were examined (Figure 3
and data not shown). Co-incubation of NHEK with the TLR4
antibody alone or an isotype control IgG did not significantly
change the expression of S100A15S or S100A15L nor the
release of IL-8 (Figure 3 and data not shown). Results
obtained from RT-PCR and ELISA analysis show that anti-
TLR4 significantly inhibits E. coli-induced effects on the
transcript levels of S100A15L (Figure 3b), and on release of
IL-8 (Figure 3c). However, an inhibiting effect of anti-TLR4 on
E. coli-induced upregulation of S100A15S was observed but
was not statistically significant (Figure 3a).
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Figure 2. Regulation of human S100A15S, S100A15L, and S100A7 mRNA in
NHEK by E. coli and LPS. (a–c) NHEKs were stimulated with E. coli for 3, 24,
or 96 hours, respectively (d) or with LPS B5:055 for 24 hours. Relative
transcript levels of (a) S100A15S, (b) S100A15L, and (c) S100A7 are shown
(densitometric quantification of S100A15S, S100A15L, and S100A7 mRNA
each over the b-actin mRNA transcript). Each bar represents the meanþ SD of
three independent experiments performed in duplicates. (d) In a next
experiment, NHEKs were non-treated (lane 1) or were stimulated with LPS
100 ng/ml (lane 2) or 1,000 ng/ml (lane 3). Graph shows the results of one
representative experiment out of three. Significance of alterations was tested
using the two-way analysis of variance (*Po0.05, **Po0.01, ***Po0.001).
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Figure 3. Inhibition of E. coli induced S100A15L expression and IL-8 release
by TLR4 blocking antibody. NHEKs were pretreated with neutralizing
antibodies against TLR4 (anti-TLR4) or control IgG (data not shown)
30 minutes before the stimulation with E. coli for 24 hours. Relative transcript
levels of (a) S100A15S and (b) S100A15L are shown (densitometric
quantification of S100A15S or S100A15L mRNA each over the b-actin mRNA
transcript). Each bar represents the meanþ SD of three independent
experiments each performed in duplicates. (c) IL-8 release was measured in
cell culture supernatants using ELISA. Data are means7SD of triplicates of
one representative experiment out of three (*Po0.05). The inhibiting effect of
anti-TLR4 on E. coli-induced S100A15S upregulation was not statistically
significant (P¼ 0.055).
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E. coli-induced mS100A15 expression in vivo is dependent on
TLR4
To further elucidate the role of E. coli-induced mS100A15
expression in mice, in vitro and in vivo experiments were
performed. To test if mS100A15, the murine ortholog of the
human S100A7/A15 family, is also regulated by E. coli,
murine keratinocytes were cultured and stimulated with heat-
killed E. coli and expression of mS100A15 was evaluated
(Figure 4a). Levels of mS100A15 mRNA were upregulated in
murine keratinocytes upon stimulation with E. coli (Figure
4a). Based on our in vitro results in human keratinocytes,
where inhibition of TLR4 abrogated E. coli-induced S100A15
expression, in vivo experiments were performed. C57BL/6
wild-type and TLR4/ mice were infected with E. coli
intracutaneously and RT-PCR and immunofluorescence
staining were performed after 24 hours. In RT-PCR analyses,
skin of wild-type mice but not of TLR4/ mice, showed
upregulation of mS100A15 after infection with E. coli (Figure
4b). These data were confirmed by immunofluorescence
staining for mS100A15 (Figure 4c), using a specific antibody
(Wolf et al., 2006). Increased staining of mS100A15 was
observed in E. coli-injected skin of wild-type mice but not in
TLR4/ mice. In wild-type mice, staining was localized
throughout the whole epidermis after infection with E. coli.
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Figure 4. Expression of mS100A15 is induced by E. coli and mediated through TLR4. (a) For in vitro studies, murine keratinocytes were stimulated with
E. coli for 24 hours and RT-PCR was performed. (a) E. coli stimulation induced upregulation of mS100A15 in murine keratinocytes. For in vivo experiments,
wild-type (WT) and TLR4/ mice were infected with E. coli for 24 hours and RT-PCR and immunofluorescence staining were performed. (b) Mouse skin
of wild-type mice (WT) upregulated mS100A15 gene expression after infection with E. coli, whereas TLR4/mice did not. Mouse skin was stained for
mS100A15 (green) and nuclei were stained with DAPI (40,6-diamidino-2-phenylindole; blue). (c) Increased staining of mS100A15 throughout the whole
epidermis was observed in E. coli-injected skin of wild-type mice but not in TLR4/ mice. Fold induction of mRNA gene expression relative to vehicle-treated
controls or wild-type mice was calculated using the 2ðDDCtÞ method, as described in Materials and Methods. In vitro stimulation experiments were
performed in triplicates and shown are means7SD from one representative experiment. Relative gene expression of mS100A15 in mouse skin is presented as
mean7SEM. Immunofluorescence stainings are representative for all mice tested (*Po0.05). Bar¼ 0.1 mm.
www.jidonline.org 2599
AS Bu¨chau et al.
S100A15: An AMP of the Skin
In control mice as well as in TLR4/ mice, a modest
staining was observed in suprabasal layers and in hair
follicles (Figure 4c). Thus, our data provide further evidence
that mS100A15 protein expression is induced by E. coli and is
regulated through TLR4 signaling.
S100A15 has antimicrobial activity against E. coli
Although human skin is capable of producing various
antimicrobial proteins with a broad spectrum of activity,
many bacteria survive on human skin, whereas E. coli is
rapidly killed (Bevins, 2005; Gla¨ser et al., 2005). To
investigate whether S100A15 has antimicrobial activity
against E. coli, we performed a colony-forming unit (CFU)
assay and minimal inhibitory concentration assays, using
recombinant S100A15. Recombinant S100A7 and/or the
AMP LL-37 were used as positive controls, because both
are well-known AMPs with killing activity against E. coli
(Gla¨ser et al., 2005; Dorschner et al., 2006). Bacterial killing
and growth inhibitory effects against E. coli were observed for
S100A15 (Figure 5a and b), suggesting a role for this protein
in skin defense against bacterial colonization.
DISCUSSION
Epithelial surfaces like the skin depend on two major
mechanisms of innate immune responses for protection
against microbes: (1) the existence of receptors to recognize
pathogens (Medzhitov and Janeway, 2000; Zhang and
Ghosh, 2000) and (2) employment of mechanisms that kill
pathogens, such as AMPs and proteins (Braff et al., 2005).
This is supported by observations in humans and animals
where deficient AMP expression is associated with increased
risk for infection (Morrison et al., 1999; Nizet et al., 2001;
Ong et al., 2002; Pu¨tsep et al., 2002). Similarly, mice
deficient in pattern recognition by lacking TLRs have been
shown to be more susceptible to infections than wild-type
mice (Branger et al., 2004). However, little is known about
the mechanisms that control AMP expression and function in
the skin upon infection with E. coli.
In this study, we demonstrate the differential regulation of
human S100A15 and S100A7 as well as the murine S100A15
in response to stimulation with microbes and bacterial
components. In primary human keratinocytes, E. coli induced
the strongest upregulation of S100A15L from all bacteria
tested. Furthermore, we demonstrate that murine and human
S100A15 orthologs are similarly regulated in keratinocytes,
supporting our previous results (Wolf et al., 2006). In vivo
studies, using TLR4/ and wild-type mice, revealed that
TLR4 signaling is important for mS100A15 regulation. These
data are in accordance with in vitro results obtained from
human keratinocytes. Induction of S100A15S and S100A15L
transcript abundance, both coding for the human protein
S100A15, was suppressed by neutralizing TLR4 antibodies. In
our experiments, this blocking effect was more pronounced
for the long splice variant S100A15L compared to the short
splice variant S100A15S. Alternative splicing is a versatile
mechanism to create diversity and flexibility in the regulation
of gene expression. It has been already described that the
composition and length of splice variants influence mRNA
transcription, processing efficiency, and half-life (Ayoubi and
Van de Ven, 1996). Hence, it is possible that one or more of
these mechanisms are responsible for the different levels of
the splice variants of human S100A15. Currently, antibodies
recognizing specifically human S100A15 are under develop-
ment and will be of great interest for future studies.
Our studies strongly suggest involvement of the TLR4
pattern recognition receptor in S100A15 regulation in skin.
TLR4 was the first human homologue of Toll to be described
(Rock et al., 1998) and was subsequently characterized as a
receptor for LPS signaling (Tapping et al., 2000; Takeda et al.,
2003). Controversial results have been reported regarding
expression and role of LPS reactivity mediated by TLR4 in
primary human keratinocytes. Some authors found TLR4 to
be expressed by primary and HaCaT keratinocytes (Song
et al., 2002; Pivarcsi et al., 2003; Lebre et al., 2007), whereas
other authors showed no TLR4 expression and no LPS
reactivity in cultured keratinocytes (Kawai et al., 2002;
Ko¨llisch et al., 2005). Our own results are consistent with this
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Figure 5. S100A15 has antimicrobial activity against E. coli. To assess
antibacterial activity against E. coli, (a) an antimicrobial assay and
(b) a minimal inhibitory concentration assay were performed. (a) E. coli
was incubated for 3 hours with 50mg/ml recombinant S100A15 or S100A7.
The number of bacterial colonies was counted and percentage of killing
activity was calculated as described in Materials and Methods. Data shown
are means7SD from three independent experiments. (b) E. coli was
co-incubated with recombinant S100A15 (10, 20, and 50 mg/ml), S100A7
(50mg/ml), and cathelicidin LL-37 (32 mM), and bacterial growth was
monitored over time to determine antimicrobial activity. Conditions not
containing recombinant proteins or containing the vehicle were used as
negative controls. Bacterial growth was measured by OD600. Data are means
of triplicates of one representative experiment out of two (*Po0.05).
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controversy, as semiquantitative PCR analysis of TLR4
expression in NHEK from mammary surgery showed positive
expression, whereas NHEKs from commercial sources were
negative for TLR4 (unpublished data). These controversial
results may be due to different culture conditions, differentia-
tion status of the cells, and origin of keratinocytes, an issue
previously described (Pivarcsi et al., 2004). In this study, we
demonstrated that in NHEK neutralizing antibodies against
human TLR4 significantly inhibited E. coli-induced IL-8
secretion and expression of S100A15L but not that of
S100A15S. We hereby demonstrate that TLR4 has a
functional role in human keratinocytes, confirming the results
described by several authors (Song et al., 2002; Pivarcsi et al.,
2003; Lebre et al., 2007). In a mouse model using wild-type
and TLR4/ mice, we demonstrated that only wild-type
mice upregulate mS100A15 expression upon E. coli infection
of the skin indicating that TLR4 is important for initiation of
an innate immune response in keratinocytes. However, we
cannot exclude that pattern recognition receptors other than
TLR4 contribute to the E. coli-induced effects on S100A15
expression. The dependence upon TLR4 for keratinocyte
responsiveness for E. coli, as demonstrated in this work, may
be direct or indirect. In vivo recognition of pathogens by TLRs
leads to the release of proinflammatory cytokines and
chemokines (Takeda et al., 2003; Akira and Takeda, 2004;
Beutler, 2004), which are responsible for the recruitment of
inflammatory cells to sites of infection and the initiation of an
enhanced immune response in keratinocytes. It is thereby
possible that upregulation of mS100A15 expression in vivo is
caused by both or either, a direct effect on keratinocytes or an
indirect effect mediated by proinflammatory cytokines
produced after E. coli infection in the skin. The inability of
E. coli to colonize healthy human skin may be due to the
efficiency of the innate immune system that employs at least
two mechanisms: first, keratinocytes rapidly recognize
pathogens and mount an antimicrobial response; second,
the same mechanism of pathogen recognition by TLRs is used
to induce an inflammatory immune response. Production of
proinflammatory IL-8 in NHEK following stimulation with E.
coli in in vitro conditions was observed here and induction in
vivo remains to be studied. However, the hypothesis of this
‘‘dual’’ mechanism of innate immune function may con-
tribute to certain skin diseases. Many AMPs have been shown
to be overexpressed in skin states going along with a strong
inflammatory component, such as psoriasis and wound
healing (Wolf et al., 2003; Lee and Eckert, 2007; Schauber
et al., 2007). Thus, recognition of pathogens in diseased skin
may result in enhanced antimicrobial and inflammatory
immune responses and may thereby result in exacerbation of
inflammation.
In order to evaluate if upregulated S100A15 expression
through bacterial components reflects protection against E.
coli, we performed antimicrobial assays identifying S100A15
as a new antimicrobial protein. Antimicrobial properties have
already been described for several members of the S100
family, including S100A7, S100A8, S100A9, and S100A12
(Gottsch et al., 1999; Gla¨ser et al., 2005). Notably,
antimicrobial activity of these calcium-binding proteins is
not dependent on calcium concentrations, but has been
shown for few S100 proteins to be associated with zinc ion
concentrations (Sohnle et al., 2000; Gla¨ser et al., 2005). Also,
it is possible that in addition to S100A15, several antimicro-
bial proteins synergize with each other, as previously
suggested for defensins and cathelicidins (Nagaoka et al.,
2000).
In summary, our results complement previous observa-
tions that E. coli has a strong and underappreciated effect on
cutaneous innate immunity through regulation of S100
proteins. In recent years, much has been learned about
how microbes and bacteria-derived molecules activate the
innate immune system. AMPs and proteins play a key role in
the innate immune response and confer resistance to
bacterial infection of the skin. Understanding the regulation
and function of S100 proteins as effector molecules of the
innate antimicrobial response might lead to new treatments
of infectious skin disease.
MATERIALS AND METHODS
Reagents
The S100A15 and S100A7 cDNA sequences, containing a 6
histidine tag sequence, were ligated into PQE30-vector (Qiagen,
Hilden, Germany). E. coli M15 were transformed with each resulting
expression vectors, and recombinant S100A15 and S100A7 proteins
were produced by E. coli M15, according to the manufacturer’s
protocol (Qiagen). E. coli M15 itself was not killed by production of
S100A15 and S100A7 probably due to strain-specific antimicrobial
activity, as it has been already observed for S100A7 (Gla¨ser et al.,
2005). Recombinant proteins were purified by Ni-NTA-agarose. The
amounts of the purified proteins were quantified by NuPAGE (10%
Bis-Tris gel) and Western Blot detection. Each recombinant protein
was kept in a solution of 1:1 phosphate-buffered saline (PBS)/
glycerine and stored at 201C until use. LPS (O55:B5) derived from
E. coli (Sigma-Aldrich, Steinheim, Germany) was used at concentra-
tions of 100 and 1,000 ng/ml that have been shown to induce a
significant cell response (Shimazu et al., 1999; Song et al., 2002;
Lebre et al., 2007). Functional-grade neutralizing anti-human TLR4
antibody (anti-TLR4), clone HTA 125, was purchased from Serotec
(Du¨sseldorf, Germany) and used at a concentration of 10 mg/ml
(Shimazu et al., 1999) and several approaches were taken to
demonstrate the specificity of this antibody (Shimazu et al., 1999).
As isotype control for the TLR4 antibody, purified mouse IgG was
used (Pharmingen, Heidelberg, Germany).
Keratinocyte culture and stimulation of keratinocytes
NHEKs were obtained from skin samples of healthy individuals
undergoing breast reduction plastic surgery after informed consent
and the use of NHEKs was approved by the ethical committee for
human research at the University of Duesseldorf. The study was
conducted according to the Declaration of Helsinki Principles. Cells
were seeded in 175 cm2 flasks at a density of 4 104 cells/cm2
maintained in a serum-free 1:1 mixture of keratinocyte-SFM (Gibco,
Eggenstein, Germany) and MCDB 153 (Biochrom, Berlin, Germany)
containing supplements (epidermal growth factor, bovine pituitary
gland extract, glutamine, and antibiotic/antimycotic mixture, all
purchased from Gibco). Keratinocytes were cultured at 371C in a
humidified atmosphere containing 5% CO2. Keratinocytes were
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cultured for three passages and were kept in supplement-free
medium for 24 hours before stimulation experiments. Normal
murine keratinocytes were a kind gift by Dr Jamora (University of
California, San Diego, CA). All bacterial strains were kindly provided
by the Department of Medical Microbiology, Heinrich Heine
University Duesseldorf, Germany and the Division of Dermatology,
University of California San Diego and VA San Diego Healthcare
System, San Diego, CA. We used standard laboratory strains for E.
coli (ATCC 25922), P. aeruginosa (ATCC 15442), and S. aureus
(ATCC 25923). For in vitro stimulation experiments, bacterial
cultures were allowed to grow in Luria-Bertani (LB) medium at
371C to a optical density (OD)600 of 0.8. Bacteria were harvested
and washed twice in PBS, diluted to working solutions and heat-
inactivated at 681C for 20 min. For some experiments, bacteria were
further centrifuged at 3,000 g for 20 minutes to obtain a super-
natant and a pellet. Heat-killed bacterial compounds were used to
stimulate NHEK corresponding to approximately 3.5 104 CFU/ml
for E. coli, 2.5 104 CFU/ml for P. aeruginosa, and 1.8x104 CFU/ml
for S. aureus per well.
RNA preparation, semiquantitative and real-time PCR
Total RNA was extracted from human keratinocytes by using the
RNAeasy Minikit (Qiagen) or from mouse skin samples and murine
keratinocytes that were homogenized in TRIZOL reagent (Invitrogen,
Karlsruhe, Germany). For mouse skin samples, a dismembrator was
used. For human keratinocytes, 1 mg of total RNA was reversibly
transcribed by Superscript II (Invitrogen), according to the manu-
facturer’s protocol. For amplification of human S100A15S,
S100A15L, S100A7, and b-actin primer pairs were used as described
previously (Wolf et al., 2003; Gla¨ser et al., 2005) and were
commercially synthesized by MWG-Biotech (MWG Biotech, Ebers-
berg, Germany). PCRs were carried out in a total volume of 20 ml,
containing 1ml of the RT sample, 2ml 10 buffer (Qiagen), 0.2 mM
dNTPs, 2 U Taq polymerase (Qiagen), and 0.2 mM of specific primer
pairs for the human S100A15 long isoform (7.1 sense 50-ACGTCA
CTCCTGTCTCTCTTTGCT-30, 6.2 antisense 50-TCATGAATCAACCC
ATTTCCTGGG-30), the S100A15 short isoform (NCBP5F sense 50-CA
AGTTCCTTCTGCTCCATCTTAG-30, NCBP4R antisense 50-AGCCTT
CAGGAAATAAAGACAATC-30), S100A7 (sense 50-AGACGTGATG
CAAGATTGAC-30, antisense 50-TGTCCTTTTTCTCAAAGACGTC-30,
b-actin (F(A) sense 50-AGAGATGGCCACGGCTGCTT-30, R(A) anti-
sense 50-ATTTGCGGTGGACGATGGAG-30). PCRs were performed
in duplicate and each PCR was performed at two cycle numbers
within the log-linear phase. The PCR conditions were 31 and 33
cycles for S100A15L, 37 and 39 cycles for S100A15S and S100A7,
and 20 and 22 cycles for b-actin at 941C for 1 minute, 561C for
1 minute, and 721C for 1 minute (þ time increment of 2 seconds/
cycle) followed by an additional extension step at 721C for
5 minutes. A negative control was set up for each reaction.
Amplicons were subjected to electrophoresis in a 1.5% agarose
gel containing 0.002% ethidium bromide. The density of amplicons
was measured by UV transillumination of the stained bands, using a
digital camera analyzing system (Multianalyst, Bio-Rad Laboratories,
Hercules, CA). The amount of each S100A15 isoform was normal-
ized by b-actin expression. For murine keratinocytes and mouse skin
samples, an iScript cDNA synthesis kit was used (Bio-Rad). For
amplification of mS100A15, real-time RT-PCR was performed.
A predeveloped Taqman assay probe was used for mS100A15
(ABI, Foster City, CA). 18S (forward primer: CGGAGGTTCGAAGACGAT
CA, reverse primer: CATCGTTTATGGTCGGAACTACG) expression
was evaluated using a SYBR Green protocol, according to the
manufacturer (ABI). Analyses were performed in triplicate in an ABI
Prism 7000 Sequence Detection System. Fold induction relative to
the vehicle-treated control was calculated using the 2(DDCt) method,
where DDCt is DCt(stimulant)DCt(control), DCt is Ct(target gene)
Ct(housekeeping gene), and CT is the cycle at which an arbitrary
detection threshold is crossed. Data are presented as meansþ SD for
human and murine keratinocytes, for mouse skin as meansþ SEM.
For statistical analysis, a Student’s t-test was performed unless
otherwise indicated. We considered a Po0.05 to be statistically
significant.
EMSA and supershift assay
EMSAs have been performed as described previously (Hassan et al.,
2004, 2005). Double-stranded oligonucleotides containing the AP-1
or NF-kB consensus sequence (Santa Cruz Biotechnology, Santa
Cruz, CA) were 50-end-labeled with [g-32P] ATPs (Hartmann
Analytica, Hilden, Germany). DNA-binding reactions were per-
formed, using 4 mg nuclear extract and 0.2 ng probe in a total volume
of 30 ml for 30 minutes at room temperature in binding buffer (10 mM
Tris, pH 7.5; 50 mm NaCl; 1 mM EDTA; 1 mM MgCl2; 0.5 mM
dithiothreitol; and 4% glycerol). The specificity of binding was
analyzed by competition with an unlabeled oligonucleotide. After
incubation, the binding reactions were loaded on a 6% native
polyacrylamide/0.5 TBE (45 mM Tris-borate and 1 mM EDTA) gel,
and run in 0.5 Tris-borate/EDTA buffer at room temperature. The
dried gel was visualized by exposure to high-performance auto-
radiography film.
Supershift assays were performed by incubation of nuclear
extracts (obtained from human keratinocytes following stimulation
with E. coli) with either anti-c-jun antibody (Sc-1694) or with anti-
p50 (Sc-7178) and/or p65 (Sc-109) antibodies (all from Santa Cruz
Biotechnology), to prove specificities of AP-1 and NF-kB DNA-
binding activities, respectively. The antibodies were preincubated
for 30 minutes at 371C with the nuclear extracts and then allowed to
incubate with 0.2 ng of the labeled oligonucleotide of AP-1 or NF-kB
for 30 minutes at room temperature. Samples were subjected to
EMSA as described above for AP-1 and NF-kB gel shift assay.
IL-8 ELISA
Human IL-8 was assayed in supernatant-stimulated NHEK using the
Quantikine human IL-8 immunoassay kit (R&D Systems, Wiesbaden,
Germany), according to the manufacturer’s instructions. The
standard curves were performed using serial dilutions of recombi-
nant human IL-8. The optical density of the wells was determined
using a microplate reader set at 450 nm.
Antimicrobial assay
E. coli (ATCC 25922) was grown until log-phase in LB medium,
centrifuged 350 g for 5 minutes, and diluted in PBS (Gibco,
calcium and magnesium free, pH 7.4) to an end concentration of
1.5 106 CFU/ml. A 50 mg/ml portion of recombinant S100A15 or
S100A7 protein or their vehicle (control) was added to the bacterial
dilutions and incubated for 3 hours. A 10ml portion of bacterial
solution with or without recombinant proteins was plated in serial
dilutions on agar plates overnight at 371C for enumeration of CFU.
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The killing activity of S100A15 and S100A7 was calculated as the
percentage of bacterial death compared to vehicle-incubated
controls expressed as [1(survival after recombinant protein
incubation)/(survival after vehicle incubation) 100].
Minimal inhibitory concentration assay
Minimal inhibitory concentration assays were performed as de-
scribed previously (Dorschner et al., 2006) with slight modifications.
Growing bacteria in media containing NaCOH3 and NaPOH4
increases the sensitivity of bacteria to AMPs (Dorschner et al., 2006).
Bacteria were seeded in a 96-well plate and recombinant proteins of
S100A15, S100A7, and synthetic LL-37 were added in concentra-
tions as indicated. As a negative control, bacteria were grown in
media only or in media containing the protein vehicle (PBS/
glycerine) for recombinant S100A15 and S100A7. OD600 was
measured at indicated time points.
Mice and E. coli infection model
All mice experiments were approved by the Veteran Affair San Diego
subcommittee on animal studies. Female C57BL/6 wild-type mice
and TLR4/ mice on C57BL/6 background were purchased from
Jackson Laboratory (Bar Harbor, ME) and kept under specified
pathogen-free conditions. Three mice of 10 weeks were used per
group. Mouse hair was removed 48 hours before the experiments
were started. For infection, E. coli was grown in LB at 371C overnight
and then subcultured until log phase. Bacteria were harvested,
washed twice in PBS, and were kept in 1:1 dilution with cytodex
beads. Bacteria (0.9 107) were injected per mouse in a volume of
100ml intracutaneously in the left flank, injection of the vehicle
followed in the right flank. Twenty-four hours after infection, mice
were killed and skin punch biopsies (0.8 mm diameter) were
obtained from bacteria- and vehicle-injected sites. Half of the skin
sample was used for immunofluorescence; the other half was used
for RT-PCR analyses.
Fluorescence immunostaining
Immunofluorescence was performed on serial 10 mM frozen sections
of mouse skin, fixed in acetone as described previously with slight
modifications (Wolf et al., 2006). Briefly, sections were blocked in
5% goat serum, and incubated overnight with mS100A15 rabbit-
derived polyclonal antibody (5 mg/ml, antibody 3961) or preimmune
serum. After washing in PBS for three times 15 minutes, slides were
reprobed with an FITC-labeled goat anti-rabbit antibody (Sigma-
Aldrich, St Louis, MO). Nuclei were stained with 40,6-diamidino-2-
phenylindole (Molecular Probes, Eugene, OR). Slides were mounted
in ProLong Anti-Fade reagent (Molecular Probes) and evaluated with
an Olympus BX41 microscope (Olympus, Melville, NY) at  100
original magnification.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Professor Dr med. Bernhard Homey from the Department of
Dermatology, Heinrich-Heine-University, Du¨sseldorf, Germany for support
and comments. We also thank all members from our laboratories for their
helpful and critical suggestions. This work was supported by a grant from
Deutsche Forschungsgemeinschaft (DFG) for R.W. (Emmy-Noether Program,
Wo 843/2-1) and by a grant from Deutsche Forschungsgemeinschaft (DFG)
for A.S.B. (BU 2212/1-1).
REFERENCES
Ambartsumian N, Tarabykina S, Grigorian M, Tulchinsky E, Hulgaard E,
Georgiev G et al. (1995) Characterization of two splice variants of
metastasis-associated human mts 1 gene. Gene 159:125–30
Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol
4:499–511
Ayoubi TA, Van de Ven WJ (1996) Regulation of gene expression by
alternative promoters. FASEB J 10:453–60
Beutler B (2002) TLR-4 as the mammalian endotoxin sensor. Curr Top
Microbiol Immunol 270:109–20
Beutler B (2004) Innate immunity: an overview. Mol Immunol 40:845–59
Bevins CL (2005) An important clue: fingerprints point to psoriasin in defense
against E. coli. Nat Immunol 6:12–3
Braff MH, Di Nardo A, Gallo RL (2005) Keratinocytes store the antimicrobial
peptide cathelicidin in lamellar bodies. J Invest Dermatol 124:394–400
Branger J, Leemans JC, Florguin S, Wejer S, Speelman P, Van der Poll T (2004)
Toll-like receptor 4 plays a protective role in pulmonary tuberculosis in
mice. Int Immunol 16:509–16
Cole AM, Kim YH, Tahk S, Hong T, Weis P, Waring AJ, Ganz T (2001)
Calcitermin, a novel antimicrobial peptide isolated from human airway
secretions. FEBS Lett 504:5–10
de Jongh J, Zeeuwen PLJM, Kucharekova M, Pfundt R, van der Valk PG, Blokx
W et al. (2005) High expression levels of keratinocyte antimicrobial
proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol
125:1163–73
Donato R (2001) S100: a multigenic family of calcium-modulated proteins of
the EF-hand type with intracellular and extracellular functional roles. Int
J Biochem Cell Biol 33:637–68
Dorschner RA, Lopez-Garcia B, Peschel A, Kraus D, Morikawa K, Nizet V
et al. (2006) The mammalian ionic environment dictates microbial
susceptibility to antimicrobial defense peptides. FASEB J 20:35–42
Eckert R, Broome A, Ruse M, Robinson N, Ryan D, Lee K (2004) S100 proteins
in the epidermis. J Invest Dermatol 123:23–33
Foell D, Roth J (2004) Proinflammatory S100 proteins in arthritis and
autoimmune disease. Arthritis Rheum 50:3762–71
Frohm M, Agerberth B, Ahangari G, Stahle-Backdahl M, Liden S, Wigzell H
et al. (1997) The expression of the gene coding for the antibacterial
peptide LL-37 is induced in human keratinocytes during inflammatory
disorders. J Biol Chem 272:15258–63
Gla¨ser R, Harder J, Lange H, Bartels J, Christophers E, Schro¨der JM (2005)
Antimicrobial psoriasin (S100A7) protects human skin from Escherichia
coli infection. Nat Immunol 6:57–64
Gottsch JD, Eisinger SW, Liu SH, Scott AL (1999) Calgranulin C has
filariacidal and filariastatic activity. Infect Immun 67:6631–6
Harder J, Schro¨der JM (2005) Psoriatic scales: a promising source for the
isolation of human skin-derived antimicrobial proteins. J Leukoc Biol
77:476–86
Hassan M, Ghozlan H, Abdel-Kader O (2004) Activation of RB/E2F signaling
pathway is required for the modulation of hepatitis C virus core protein-
induced cell growth in liver and non-liver cells. Cell Signal 16:
1375–85
Hassan M, Ghozlan H, Abdel-Kader O (2005) Activation of c-Jun NH2-
terminal kinase (JNK) signaling pathway is essential for the stimulation of
Hepatitis C Virus (HCV) non-structural protein 3 (NS3)-mediated cell
growth. Virology 333:324–36
Kawai K, Shimura H, Minagawa M, Ito A, Tomiyama K, Ito M (2002)
Expression of functional Toll-like receptor 2 on human epidermal
keratinocytes. J Dermatol Sci 30:185–94
Ko¨llisch G, Kalali BN, Voelecker V, Wallich R, Behrendt H, Ring J et al.
(2005) Various members of the Toll-like receptor family contribute to the
innate immune response of human epidermal keratinocytes. Immunol-
ogy 114:531–41
Komine M, Rao LS, Kaneko T, Tomic-Canic M, Tamaki K, Freedberg IM et al.
(2000) Inflammatory versus proliferative processes in epidermis. Tumor
necrosis factor alpha induces K6b keratin synthesis through a transcrip-
www.jidonline.org 2603
AS Bu¨chau et al.
S100A15: An AMP of the Skin
tional complex containing NFkappa B and C/EBPbeta. J Biol Chem
275:32077–88
Kulski JK, Lim CP, Dunn DS, Bellgrad M (2003) Genomic and phylogenetic
analysis of the S100A7 (Psoriasin) gene duplications within the region of
the S100 gene cluster on human chromosome 1q21. J Mol Evol
56:397–406
Lebre MC, van der Aar AM, van Baarsen L, van Capel TM, Schuitenmaker JH,
Kapsenberg ML et al. (2007) Human keratinocytes express functional
Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 127:331–41
Lee KC, Eckert RL (2007) S100A7 (Psoriasin) – mechanism of antibacterial
action in wounds. J Invest Dermatol 127:945–57
Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME (1989)
Interaction of human defensins with Escherichia coli. Mechanism of
bactericidal activity. J Clin Invest 84:553–61
Medzhitov R, Janeway CA (2000) Innate immunity. N Engl J Med 343:338
Mirmohammadsadegh A, Tschakarjan E, Ljoljic A, Bohner K, Michel G,
Ruzicka T et al. (2000) Calgranulin C is overexpressed in lesional
psoriasis. J Invest Dermatol 114:1207–8
Morrison GM, Davidsom DJ, Dorin JR (1999) A novel mouse beta defensin,
Defb2, which is upregulated in the airways by lipopolysaccharide. FEBS
Lett 442:112–6
Nagaoka I, Hirota S, Yomogida S, Ohweda A, Hirata M (2000) Synergistic
actions of antimicrobial neurtophil defensins and cathelicidins. Inflamm
Res 49:73–9
Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudsill J, Dorschner RA et al.
(2001) Innate antimicrobial peptide protects the skin from invasive
bacterial infection. Nature 414:454–7
Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T et al.
(2002) Endogenous antimicrobial peptides and skin infections in atopic
dermatitis. N Engl J Med 347:1151–60
Pivarcsi A, Koreck A, Bodai L, Szell M, Szeg C, Belso N et al. (2004)
Differentiation-regulated expression of Toll-like receptors 2 and 4 in
HaCaT keratinocytes. Arch Dermatol Res 296:120–4
Pivarcsi A, Bodai L, Rethi B, Kenderssy-Szabo A, Koreck A, Szell M et al.
(2003) Expression and function of Toll-like receptors 2 and 4 in human
keratinocytes. Int Immun 15:721–30
Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X et al. (1998)
Defective LPS signalling in C3H/Hej and C57BL/10ScCR mice: muta-
tions in Tlr4 gene. Science 282:2085–8
Pu¨tsep K, Carlsson G, Boman HG, Andersson M (2002) Deficiency of
antimicrobial peptides in patients with morbus Kostmann: an observa-
tion study. Lancet 360:1144–9
Qin JZ, Chaturverdi V, Denning MF, Choubey D, Diaz MO, Nickoloff BJ
(1999) Role of NF-kappaB in the apoptotic-resistant phenotype of
keratinocytes. J Biol Chem 274:37957
Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF (1998) A family of
human receptors related to Drosophila Toll. Proc Natl Acad Sci USA
95:588–93
Santamaria-Kisiel L, Rintala-Dempsey AC, Dhaw GS (2006) Calcium-
dependent and -independent interactions of the S100 protein family.
Biochem J 396:201–14
Schauber J, Dorschner RA, Coda AB, Bu¨chau AS, Liu PT, Kiken D et al. (2007)
Injury enhances TLR2 function and antimicrobial peptide expression
through a vitamin D-dependent mechanism. J Clin Invest 117:
803–811
Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K et al. (1999)
MD-2, a molecule that confers lipopolysaccharide responsiveness on
Toll-like receptor 4. J Exp Med 189:1777–82
Sohnle PG, Hunter MJ, Hahn B, Chazin WJ (2000) Zinc-reversible
antimicrobial activity of recombinant calprotectin (migration inhibitory
factor-related proteins 8 and 14). J Infect Dis 182:1272–5
Song PI, Park YM, Abraham T, Harten B, Zivony A, Nepardize N et al. (2002)
Human keratinocytes express functional CD14 and Toll-like receptor 4.
J Invest Dermatol 119:424–32
Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol
21:335–76
Takeuchi O, Hoshino K, Kawaei T, Sanjo H, Takada H, Ogawa T et al. (1999)
Differential roles of TLR2 and TLR4 in recognition of Gram-negative
and Gram-positive bacterial cell wall components. Immunity 11:
443–451
Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS (2000) Toll-like
receptor 4, but not Toll-like receptor 2, is signalling receptor for
Escherichia and Salmonella lipopolysaccharides. J Immunol 165:5780–7
Wolf R, Mirmohammadsadegh A, Walz M, Lysa B, Tartler U, Remus R et al.
(2003) Molecular cloning and characterization of alternatively splice
mRNA isoforms from psoriatic skin encoding a new member of the S100
family. FASEB J 17:1969–71
Wolf R, Voscopopulos CJ, FitzGerald PC, Goldsmith P, Cataisson C, Gunsior
M et al. (2006) The mouse S100A15 ortholog parallels genomic
structure, gene expression, and protein-processing pattern of the human
S100A7/A15 subfamily during epidermal maturation. J Invest Dermatol
126:1600–8
Zhang G, Ghosh S (2000) Molecular mechanisms of NF-kappaB activation
induced by bacterial lipopolysaccharide through Toll-like receptors.
J Endotoxin Res 6:453–7
2604 Journal of Investigative Dermatology (2007), Volume 127
AS Bu¨chau et al.
S100A15: An AMP of the Skin
